AI assistant
CRISPR Therapeutics AG — Director's Dealing 2018
Dec 19, 2018
30936_dirs_2018-12-19_471a82f0-80a1-4b87-a9d0-5d3f45e95cf0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2018-12-17
Reporting Person: EMSTER KURT VON (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-12-17 | Common Shares | S | 3009 | $33.1662 | Disposed | 1234193 | Indirect |
| 2018-12-18 | Common Shares | S | 69925 | $29.7047 | Disposed | 1164268 | Indirect |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.03 to $33.29 per share, inclusive.
F2: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
F3: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI.
F4: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.18 to $30.62 per share, inclusive.